公开(公告)号：US20230201260A1

公开(公告)日：2023-06-29

申请号：US18056544

申请日：2022-11-17

Applicant: CELLECTIS

Inventor： Roman GALETTO ,  Agnes GOUBLE ,  Stephanie GROSSE ,  Cécile SCHIFFER-MANNIOUI ,  Laurent POIROT ,  Andrew SCHARENBERG ,  Julianne SMITH

IPC: A61K35/17 ,  C12N5/0783 ,  C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  C12N15/85

CPC classification number: A61K35/17 ,  C12N5/0636 ,  C07K16/2803 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C12N15/85 ,  C07K2317/622 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2502/99 ,  C07K2319/00 ,  C12N2501/39 ,  C12N2501/599 ,  A61K38/00

Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US20180134795A1

公开(公告)日：2018-05-17

申请号：US15314337

申请日：2015-06-17

Applicant: CELLECTIS

Inventor： Roman GALETTO

IPC: C07K16/28 ,  C07K14/735 ,  C07K14/705 ,  C12N15/85 ,  A61K35/17

CPC classification number: C07K16/2866 ,  A61K35/17 ,  A61K35/26 ,  A61K39/0011 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K14/70503 ,  C07K14/70517 ,  C07K14/70535 ,  C07K2319/03 ,  C12N15/85

Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs, which are made specific to the antigen CD123. Such CARs aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen CD123. The alpha, beta and gamma polypeptides composing these CARs are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer, especially leukemia.

公开(公告)号：US20170183413A1

公开(公告)日：2017-06-29

申请号：US15126540

申请日：2015-03-19

Applicant: CELLECTIS

Inventor： Roman GALETTO

IPC: C07K16/28 ,  C07K14/725

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  C07K14/7051 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/62 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/30

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.

公开(公告)号：US20190216854A1

公开(公告)日：2019-07-18

申请号：US16361438

申请日：2019-03-22

Applicant: Cellectis

Inventor： Roman GALETTO ,  Agnes GOUBLE ,  Stephanie GROSSE ,  Cecile MANNIOUI ,  Laurent POIROT ,  Andrew SCHARENBERG ,  Julianne SMITH

IPC: A61K35/17 ,  C07K14/705 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K38/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/74 ,  C12N5/0636 ,  C12N2501/39 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2502/99 ,  C12N2510/00

Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US20180021379A1

公开(公告)日：2018-01-25

申请号：US15711289

申请日：2017-09-21

Applicant: Cellectis

Inventor： Roman GALETTO ,  Agnes GOUBLE ,  Stephanie GROSSE ,  Cecile MANNIOUI ,  Laurent POIROT ,  Andrew SCHARENBERG ,  Julianne SMITH

IPC: C07K14/725 ,  C12N5/0783 ,  C07K14/705 ,  C07K16/28 ,  A61K38/00

CPC classification number: A61K35/17 ,  A61K38/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/74 ,  C12N5/0636 ,  C12N2501/39 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2502/99 ,  C12N2510/00

Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US20170051037A1

公开(公告)日：2017-02-23

申请号：US15308047

申请日：2015-04-30

Applicant: CELLECTIS

Inventor： Roman GALETTO

IPC: C07K14/735 ,  C07K16/28

CPC classification number: C07K14/70535 ,  C07K14/7051 ,  C07K16/2806 ,  C07K2317/622 ,  C07K2319/03 ,  C12N5/0636 ,  C12N2510/00

Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs, which are made specific to the antigen CS1. Such CARs aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen CS1. The alpha, beta and gamma polypeptides composing these CARs are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer, especially multiple myeloma.

Abstract translation: 本发明涉及被称为多链CAR的新一代嵌合抗原受体（CAR），其被制成对抗原CS1特异性。 这样的CAR旨在将免疫细胞特异性和反应性转向表达肿瘤抗原CS1的恶性细胞。 构成这些CAR的α，β和γ多肽被设计为在并置的位置组装，其形成更接近天然受体的柔性结构，其赋予最佳的信号转导。 本发明包括多核苷酸，编码所述多链CAR的载体和在其表面表达它们的分离细胞，特别是其用于免疫治疗。 本发明开辟了治疗癌症，特别是多发性骨髓瘤的高效过继免疫治疗策略。

公开(公告)号：US20160222410A1

公开(公告)日：2016-08-04

申请号：US14915434

申请日：2014-09-02

Applicant: CELLECTIS

Inventor： Andrew SCHARENBERG ,  Julianne SMITH ,  Roman GALETTO

IPC: C12N15/86 ,  C12N7/00

CPC classification number: C12N15/86 ,  C12N7/00 ,  C12N2740/17043 ,  C12N2740/17052

Abstract: The present invention relates to viral transformation method, particularly foamy virus-mediated transformation method. The present invention relates to the transfer of transgene into cells by the safe and efficient transfer of RNA encoding foamy components. The present invention has therefore therapeutic interest, especially in the field of gene therapy.

Abstract translation: 本发明涉及病毒转化方法，特别是泡沫病毒介导的转化方法。 本发明涉及通过安全有效地转移编码泡沫组分的RNA将转基因转移到细胞中。 因此，本发明具有治疗兴趣，特别是在基因治疗领域。

公开(公告)号：US20230056268A1

公开(公告)日：2023-02-23

申请号：US17716102

申请日：2022-04-08

Applicant: CELLECTIS

Inventor： Roman GALETTO ,  Agnes GOUBLE ,  Stephanie GROSSE ,  Cécile SCHIFFER-MANNIOUI ,  Laurent POIROT ,  Andrew SCHARENBERG ,  Julianne SMITH

IPC: A61K35/17 ,  C12N9/22 ,  C12N5/0783

Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to highly efficient adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US20210220405A1

公开(公告)日：2021-07-22

申请号：US17198505

申请日：2021-03-11

Applicant: Cellectis

Inventor： Roman GALETTO ,  Agnes GOUBLE ,  Stephanie GROSSE ,  Cecile MANNIOUI ,  Laurent POIROT ,  Andrew SCHARENBERG ,  Julianne SMITH

IPC: A61K35/17 ,  C07K14/705 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28

Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US20210163612A1

公开(公告)日：2021-06-03

申请号：US17124971

申请日：2020-12-17

Applicant: CELLECTIS

Inventor： Roman GALETTO

IPC: C07K16/28 ,  C07K14/725

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.